{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:42:49Z","timestamp":1780407769891,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vancomycin\u2010resistant <jats:italic>Enterococci<\/jats:italic> (VRE) infections cause significant morbidity and mortality in liver transplant (LT) recipients. Management is challenging, especially in the setting of daptomycin resistance (DR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Single\u2010center retrospective review of patients who underwent LT between January 1, 2020, and December 31, 2022, and developed VRE infections. Descriptive statistics were used and Kaplan\u2010Meier curves estimated freedom from treatment failure and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010two patients (median age 58; 64% female; 67% white) were included. Alcohol\u2010related cirrhosis (48%) and metabolic dysfunction\u2010associated steatohepatitis (31%) were the most common indications for LT, and most were from deceased donors (86%). VRE infection occurred at a median of 21 days after LT, and 16% had known prior VRE colonization. Common infection sites were blood (45%, <jats:italic>n<\/jats:italic> = 19), intraabdominal (36%, <jats:italic>n<\/jats:italic> = 15), and urine (36%, <jats:italic>n<\/jats:italic> = 15). Most were initially treated with daptomycin alone (64%) or in combination with other agents (21%); 7% received linezolid alone. Twelve (29%) developed breakthrough infections during treatment and 11 (26%) had recurrent infections after discontinuation of treatment. All\u2010cause mortality was 36% (<jats:italic>n<\/jats:italic> = 15) at a median of 90 days after VRE infection diagnosis and was nearly twice as high in patients with DR (63%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>VRE infection in LT recipients relapsed or recurred in over 25%. Mortality was high, especially in cases with DR. More data is needed to establish an optimal treatment approach, particularly for relapse and DR.\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/tid14387-gra-0001-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text><\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.14387","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T16:04:53Z","timestamp":1728144293000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of vancomycin\u2010resistant <i>Enterococci<\/i> and daptomycin\u2010resistant <i>Enterococci<\/i> infections in liver transplant recipients in a single academic center"],"prefix":"10.1111","volume":"26","author":[{"given":"Aldo","family":"Barajas\u2010Ochoa","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Surgery Division of Transplant Surgery Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tucker","family":"Smith","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-3479","authenticated-orcid":false,"given":"Idris","family":"Yakubu","sequence":"additional","affiliation":[{"name":"Department of Surgery Division of Transplant Surgery Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1310-6527","authenticated-orcid":false,"given":"Lora","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-4558","authenticated-orcid":false,"given":"David","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Surgery Division of Transplant Surgery Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-1215","authenticated-orcid":false,"given":"Nicole","family":"Vissichelli","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases Virginia Commonwealth University  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"11","key":"e_1_2_10_2_1","first-page":"741","article-title":"Infectious complications after liver transplantation","volume":"11","author":"Hernandez MDP","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13549"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00843\u201021"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000296"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad193"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399\u20103062.2003.00024.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw815"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv007"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12523"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12856"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1881153"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2020.241"},{"key":"e_1_2_10_14_1","unstructured":"EM100 Connect.CLSI M100 ED33:2023. Accessed: Nov 22 2023http:\/\/em100.edaptivedocs.net\/GetDoc.aspx?doc=CLSI%20M100%20ED33:2023&scope=user"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab659"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.07.018"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010019\u20104093\u20101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01715\u201019"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1435"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.10.020"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/498903"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245091"},{"key":"e_1_2_10_26_1","unstructured":"USFDA.Eravacycline \u2013 Injection Products. FDA. 2022. Accessed: Feb 13 2024https:\/\/www.fda.gov\/drugs\/development\u2010resources\/eravacycline\u2010injection\u2010products"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.14387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T04:52:49Z","timestamp":1735015969000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.14387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/tid.14387"],"URL":"https:\/\/doi.org\/10.1111\/tid.14387","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"2024-03-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14387"}}